TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02799420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France
Description: The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: white light endoscopy (WLE)
Description: The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
Study: NCT03277820

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probactiol Mini
Description: 6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
Study: NCT02426489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI + PEM image
Description: Effect of positron emission mammography on diagnostic accuracy
Study: NCT01733212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
Study: NCT04319497

Intervention type: DEVICE
Group type: OTHER
Intervention: Subjective refraction
Description: Subjective refraction measurements will be performed by two testers for all the patients included

Intervention type: DEVICE
Group type: OTHER
Intervention: Autorefraction
Description: Five autorefraction measurements will be performed for all the patients included

Intervention type: DEVICE
Group type: OTHER
Intervention: Wavefront aberrometry
Description: Five wavefront measurements will be performed for all the patients included
Study: NCT02820532

Intervention type: DEVICE
Group type: OTHER
Intervention: Protura Treatment table
Description: The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
Study: NCT02486341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Continuous glucose monitoring system over 120-hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Continuous glucose monitoring system over 120-hour period.
Study: NCT04613843

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water Stirring
Description: Following an active heating protocol, the cooling intervention includes vigorous water stirring throughout cold water immersion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Water Stirring
Description: Following an active heating protocol, the cooling intervention includes no water stirring throughout cold water immersion.
Study: NCT03253562

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin Pill
Description: a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus

Intervention type: DRUG
Group type: OTHER
Intervention: Vildagliptin 50 mg
Description: Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
Study: NCT04532580

Intervention type: DEVICE
Intervention: Diagnosis of fracture on X-Ray Radiographs
Description: Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software

Intervention type: DEVICE
Intervention: Diagnosis of fracture on X-Ray Radiographs
Description: Diagnosis of fracture on X-Ray Radiographs with and without the assistance of Boneview Software
Study: NCT03874429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2259
Description: Sodium Hyaluronate and Trehalose

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed multi
Description: HA
Study: NCT05273073

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Each sachet consists of 30 billion colony-forming units (CFU) of six viable probiotic strains (Lactobacillus acidophilus BCMC® 12130 (107 mg), Lactobacillus casei subsp. BCMC® 12313 (107 mg), Lactobacillus lactis BCMC® 12451 (107 mg), Bifidobacterium bifidum BCMC® 02290 (107 mg), Bifidobacterium infantis BCMC® 02129 (107 mg), and Bifidobacterium longum BCMC® 02120 (107 mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo samples were identical to the probiotics in term of taste and texture without live microbial cells.
Study: NCT01406418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 15 mg/kg
Description: Administered as a single 2-hour intravenous infusion
Study: NCT02457234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultural immersion
Description: The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
Study: NCT02160002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weaning from an incubator at a lower weight (1600 grams)
Description: Infants will be weaned from an incubator at a lower weight (1600 grams)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weaning from an incubator at a higher weight (1800 grams)
Description: Infants will be weaned from an incubator at a higher weight (1800 grams)
Study: NCT00072527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02937584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI (PT001) 14.4 μg
Description: Glycopyrronium
Study: NCT01406418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 30 mg/kg
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 30 mg/kg
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261 50 mg/kg
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion
Study: NCT00641420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser Resurfacing
Study: NCT02937584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005) 9.6 μg
Description: Formoterol Fumarate
Study: NCT04107675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A
Description: Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A
Description: Liposomal Cyclosporine A is administered at different dosages in the first two arms (10 mg bid and 5 mg bid, respectively) with a new technology of nebulizing liquid drugs, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal Placebo
Description: Liposomal Placebo is administered with the same new technology of nebulizing liquid drugs used for L-CsA, creating an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study: NCT03959683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trilogy Lithotrite
Description: The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The ShockPulse-SE Lithotripsy System
Description: The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
Study: NCT04132011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Opioid Formulation, Shortened Intervals
Description: Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Opioid Formulation, Standard intervals
Description: Extended release opioid, individualized total daily dose, dosing interval is every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Lactose pill manufactured to mimic extended release opioid formulation
Study: NCT02819232

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Detection of bacteria will be performed on a blood sample
Study: NCT03673397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, bicycle ergometer
Description: Exercise performed below individual anaerobic threshold for 30 minutes
Study: NCT02685059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Anti PD-L1)
Description: MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).
Study: NCT04132011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Lactose pill manufactured to mimic extended release opioid formulation
Study: NCT00815763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginsenoside-Rd
Description: infusion ginsenoside-Rd 20 mg once a day and continued for 14 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion placebo once a day and continued for 14 day
Study: NCT02457234

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cultural immersion
Description: The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
Study: NCT03252509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous radiologic gastrostomy
Description: Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
Study: NCT02685059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m² weekly for 12 weeks
Study: NCT02466594

Intervention type: DEVICE
Group type: OTHER
Intervention: Hilotherm Clinic®
Description: Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
Study: NCT01137539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gynecare TVT-SECUR system
Description: All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
Study: NCT03410862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elderberry Extract
Description: Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
Study: NCT03851939

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoinfusion (TAI) Combine Toripalimab
Description: Transarterial Chemoinfusion (TAI) Combine Toripalimab
Study: NCT02377102

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 12 weeks of supervised physical therapy.
Study: NCT03453892

Intervention type: DRUG
Intervention: Nivolumab
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.

Intervention type: RADIATION
Intervention: Radiotherapy
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.

Intervention type: RADIATION
Intervention: Radiotherapy
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.

Intervention type: DRUG
Intervention: Ipilimumab
Description: The normal clinical treatment-plan of the underlying disease remains unchanged.
Study: NCT03242655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCV GET-Up (Group Evaluation and Treatment Uptake)
Description: Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
Study: NCT03780998

Intervention type: DRUG
Intervention: Life7
Description: Life7 will used on the perianal skin with finger tips

Intervention type: DRUG
Intervention: Life7
Description: Life7 will used on the perianal skin with finger tips

Intervention type: DRUG
Intervention: Life7
Description: Life7 will used on the perianal skin with finger tips

Intervention type: DRUG
Intervention: Life7
Description: Life7 will used on the perianal skin with finger tips

Intervention type: DRUG
Intervention: Life7
Description: Life7 will used on the perianal skin with finger tips
Study: NCT02612909

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVACFLU-A/H5N1 vaccine
Description: Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVACFLU-A/H5N1 vaccine
Description: Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1 vaccine
Description: Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
Study: NCT03817671

Intervention type: OTHER
Group type: OTHER
Intervention: 5% O2
Description: Culturing embryos in 5% O2 just after thawing and till embryo transfer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% O2
Description: Culturing embryos in 2% O2 just after thawing and till embryo transfer
Study: NCT01238003

Intervention type: OTHER
Intervention: Interpretation of blood test results
Description: Interpretation of blood test results
Study: NCT02685059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin 90 mg/m² 2-weekly for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
Study: NCT01879644

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NF

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NF

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SM

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SM

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SU

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SU
Study: NCT01797406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water injection
Description: Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
Study: NCT00382642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Cognitive Behavioral Therapy
Description: 13 week outpatient trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy
Description: 13 week outpatient trial
Study: NCT01819285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Orchiectomy or depot LHRH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Orchiectomy or depot LHRH
Study: NCT05537870

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cancer nurse navigator care
Description: oncology case manager care combined with cancer nurse navigator care

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: case manager care
Description: case manager care (usual care)
Study: NCT00622271

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Therapy
Description: Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
Study: NCT00940472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMMET-01
Description: 90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: 90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)